Ipilimumab: How It Works, Uses, and Potential Side Effects

Ipilimumab is a monoclonal antibody that treats cancer by removing a natural brake on the immune system, allowing T cells to recognize and attack tumors more aggressively. It was the first checkpoint inhibitor to receive FDA approval, earning that distinction in 2011 for metastatic melanoma, and it fundamentally changed how oncologists think about treating advanced cancers.¹ The drug has since expanded into kidney cancer, mesothelioma, and other tumor types, but its power comes with a distinctive set of immune-related side effects that require careful monitoring.

How Ipilimumab Works

Your immune system has a built-in safeguard to prevent T cells from overreacting. A protein called CTLA-4, found on the surface of activated T cells, acts as an off switch. It competes with a stimulatory protein called CD28 for the same binding partners on immune cells that present threats to the body. CTLA-4 binds those partners far more tightly than CD28, so when CTLA-4 is active, it wins the competition and dials down the immune response.² Under normal circumstances, this keeps your immune system from attacking your own tissues. But cancer cells exploit this checkpoint, essentially hiding behind the immune system’s own restraint.

Ipilimumab is a fully human antibody that physically blocks CTLA-4, preventing it from sending that stop signal. Structural studies show the antibody latches onto the same surface of CTLA-4 that would normally contact its binding partners, creating a direct steric clash that keeps the brake from engaging.¹ With the brake released, T cells can proliferate and mount a stronger attack against tumor cells.³

One important detail is where this happens. CTLA-4 primarily regulates T cells early in the immune response, in the lymph nodes, where T cells first learn about threats. Another checkpoint, PD-1, suppresses T cells later, out in the peripheral tissues where tumors live.⁴ This distinction matters because it explains why ipilimumab and PD-1 blockers like nivolumab complement each other: one unleashes T cells at their starting point, and the other keeps them active when they arrive at the tumor.

Approved Uses in Cancer Treatment

Ipilimumab’s first and best-known approval is for advanced melanoma. In the landmark trial that led to FDA approval, patients with metastatic melanoma who received ipilimumab alone had a median overall survival of about 10 months, which was a meaningful improvement over the control arm.⁵ What made the results striking was not just the median survival but what happened at the tail end of the curve. A pooled analysis of nearly 1,900 patients across multiple trials found that the survival curve began to plateau around the three-year mark, with roughly one in five patients still alive years later.⁶ For a cancer that had been nearly untreatable at that stage, a durable plateau in survival was a genuinely new phenomenon.

Beyond melanoma, ipilimumab has gained approval for advanced kidney cancer. In intermediate- and poor-risk patients with renal cell carcinoma, the combination of nivolumab plus ipilimumab produced an objective response rate of about 42%, compared with 27% for the standard targeted therapy sunitinib, and the complete response rate was 9% versus 1%.⁷ The combination has also been studied in rarer subtypes of kidney cancer. In non-clear cell renal cell carcinoma, a phase 3b/4 trial showed a response rate of about 20% and a median overall survival of roughly 21 months.⁸

Malignant pleural mesothelioma is another approval. This aggressive cancer, strongly linked to asbestos exposure, had seen little progress in treatment for years. The CheckMate-743 trial showed that nivolumab plus ipilimumab improved median overall survival to about 18 months compared with 14 months for chemotherapy. The benefit was particularly dramatic in patients with the non-epithelioid subtype, where median survival nearly doubled from roughly 9 months to about 17 months.⁹

Ipilimumab has also been investigated in lung cancer, though its role there is less central. Early-phase data combining ipilimumab with chemotherapy in non-small cell lung cancer showed modest improvements in immune-related progression-free survival.¹⁰ More broadly, the cost of combining two checkpoint inhibitors can limit access, a tension that health policymakers continue to grapple with as these regimens become standard of care.¹¹

Why Ipilimumab Is Usually Given with Nivolumab

You will rarely see ipilimumab used alone anymore. In advanced melanoma, the combination of nivolumab plus ipilimumab produced a five-year overall survival rate of 52%, compared with 44% for nivolumab alone and 26% for ipilimumab alone.¹² The median overall survival in the combination arm exceeded five years, a number that was essentially unheard of in metastatic melanoma before immunotherapy. That said, the combination produces significantly more severe side effects than either drug alone, which has shaped how researchers develop new regimens.¹³

The logic of the combination goes back to the mechanism. Ipilimumab unleashes T cells in the lymph nodes during the priming phase, while nivolumab keeps those T cells active in the tumor’s neighborhood. Hitting both checkpoints at once attacks immune suppression at two different stages, and the clinical data consistently shows this translates into better outcomes across multiple cancer types.

Immune-Related Side Effects

Because ipilimumab removes a fundamental brake on the immune system, the side effects it causes are unlike those of traditional chemotherapy. Instead of hair loss, nausea, and low blood counts, ipilimumab triggers autoimmune-like reactions where the revved-up immune system attacks healthy tissues. Oncologists call these immune-related adverse events, and they can affect virtually any organ system.

The gastrointestinal tract is the most commonly affected organ. Diarrhea is frequent and can range from mild looseness to severe colitis with bloody stools and abdominal pain. In one detailed study of ipilimumab-induced colitis, all patients developed diarrhea, with stool frequency ranging from 3 to 20 times per day; about a quarter also had rectal bleeding.¹⁴ Symptoms usually appeared after two infusions of the drug and were treated with corticosteroids. In cases that did not respond to steroids, infliximab was used. When biopsied, the inflamed colon showed patterns resembling inflammatory bowel disease, including crypt abscesses and chronic architectural changes.¹⁴

The endocrine system is another frequent target. Inflammation of the pituitary gland, called hypophysitis, occurs in up to 9% of patients on checkpoint inhibitors, while thyroid dysfunction affects up to 15%. Adrenal inflammation is less common, occurring in about 1% of patients. On average, these endocrine side effects appear about 9 weeks after starting treatment, though the range can extend from 5 to 36 weeks.¹⁵ Unlike colitis, which often resolves with treatment, some endocrine damage is permanent, and patients may need hormone replacement therapy for the rest of their lives.

The liver, skin, and lungs are also vulnerable. Hepatitis from ipilimumab can show up as elevated liver enzymes on blood tests, sometimes with fatigue and jaundice. Skin reactions range from itchy rashes to more serious conditions. Lung inflammation, or pneumonitis, is less common with ipilimumab alone but becomes more of a concern when it is combined with nivolumab. Rare but dangerous side effects include inflammation of the heart muscle, neurological complications, and blood disorders.

How Side Effects Are Managed

The standard approach to managing ipilimumab side effects follows a severity grading system. For mild reactions, the drug can usually continue while the medical team monitors closely. For moderate reactions, treatment is typically paused and corticosteroids may be started. For severe reactions, ipilimumab is suspended and high-dose corticosteroids are initiated, with the steroid taper lasting at least four to six weeks. In refractory cases, stronger immunosuppressive agents may be needed.¹⁶

Gastrointestinal toxicity has its own management pathway. The initial treatment for ipilimumab-induced colitis or hepatitis is moderate-dose corticosteroids. For colitis that does not respond to steroids, infliximab is the standard rescue therapy. For steroid-refractory hepatitis, high-dose intravenous methylprednisolone has been used successfully, along with other immunosuppressive agents like mycophenolate mofetil.¹⁷ The optimal dosing and duration of these treatments have not been rigorously studied in randomized trials, so clinicians often adjust based on individual patient response.

One tricky aspect of managing these side effects is timing. Because ipilimumab’s immune effects build over weeks, side effects can appear long after the last infusion. A patient may feel fine during treatment and develop colitis or hepatitis weeks later. Medical teams counsel patients to report new symptoms promptly, even months after their last dose, because early intervention with steroids tends to produce better outcomes than waiting.

Dose Matters More Than You Might Expect

Ipilimumab has been studied at multiple dose levels, and the difference in toxicity between doses is substantial. A phase 3 trial directly compared 10 mg/kg and 3 mg/kg in melanoma patients. Serious treatment-related adverse events occurred in about 37% of patients at the higher dose, compared with 18% at the lower dose. Treatment-related deaths also occurred, though they were uncommon at both dose levels.¹⁸ When ipilimumab is used in combination with nivolumab, the ipilimumab component is typically given at a lower dose (often 1 mg/kg) for a limited number of cycles, which helps keep toxicity manageable while preserving the benefit of dual checkpoint blockade.

Long-Term Outcomes and the Survival Plateau

The most encouraging feature of ipilimumab-based therapy is the durability of responses for those who do respond. In melanoma, researchers have now followed patients for a decade after treatment with the nivolumab-plus-ipilimumab combination. The progression-free survival curves plateau after about three years, meaning that patients who reach that mark without their cancer progressing have a strong chance of remaining disease-free long term.¹⁹

Real-world data, which captures how drugs perform outside the controlled environment of clinical trials, has also been tracked. A large analysis of advanced melanoma patients found a five-year overall survival rate of about 36% and a five-year progression-free survival rate of roughly 20%.²⁰ These numbers are somewhat lower than the controlled trial data, which is expected since real-world populations include older and sicker patients. But the same plateau pattern holds: patients who survive beyond the three-year mark tend to keep doing well.

Why Some Patients Don’t Respond

For all its success, ipilimumab does not work for everyone. Understanding why some tumors resist it is an active area of research. One key finding involves the interferon-gamma signaling pathway, which T cells use to communicate with and kill cancer cells. In a study comparing tumors from patients who responded to ipilimumab and those who did not, non-responders had dramatically more genetic defects in the interferon-gamma pathway. Three-quarters of non-responders had copy-number losses in critical genes involved in this pathway, while none of the responders did.²¹ In plain terms, even if ipilimumab successfully activates T cells, those T cells need functional communication channels to destroy the tumor. When the tumor has lost the molecular machinery to receive those signals, the immune attack falls flat.

Resistance also arises from the tumor’s surrounding environment. Tumors can recruit suppressive immune cells, alter their metabolism to starve incoming T cells of nutrients, or turn on alternative immune checkpoints that ipilimumab does not block. T cells themselves can become exhausted over time, losing their ability to fight even when checkpoints are removed.²² This is one reason why researchers are so interested in combinations that attack the tumor from multiple angles simultaneously.

The Gut Microbiome Connection

An unexpected finding from ipilimumab research is the role of gut bacteria in determining both treatment response and side effects. In a study of metastatic melanoma patients, those whose baseline gut microbiome was enriched with certain bacteria, particularly Faecalibacterium and other Firmicutes, had significantly longer progression-free survival compared with patients whose microbiome was dominated by Bacteroides species.²³ The same microbial signatures that predicted better treatment response were also associated with the development of colitis, creating an uncomfortable paradox: the patients most likely to benefit from ipilimumab may also be the ones most likely to suffer its most common severe side effect.

This research is still in its early stages, but it has opened up the possibility that profiling a patient’s gut bacteria before treatment could help predict who will respond and who might need more aggressive monitoring for gastrointestinal complications. There is also interest in whether modifying the gut microbiome through diet, probiotics, or fecal transplants could improve outcomes, though none of these interventions are standard practice yet.

Next-Generation CTLA-4 Drugs

The biggest limitation of ipilimumab is that its immune activation is not selective. It removes the brake on T cells throughout the body, which is why it triggers autoimmune side effects in organs far from the tumor. A new wave of drugs aims to solve this problem by designing CTLA-4 blockers that activate preferentially within the tumor environment while remaining inert in healthy tissues.

One approach uses what are sometimes called “prodrug” antibodies. These are engineered so that the antibody’s tumor-binding region is masked until it encounters enzymes that are abundant in tumors but scarce in normal tissue. In mouse models, one such design depleted suppressive immune cells within tumors and boosted cancer-specific T cell responses while causing less toxicity than standard CTLA-4 blockade.²⁴ Another next-generation drug, called LM-168, is engineered to bind CTLA-4 strongly only in the acidic, enzyme-rich microenvironment of tumors while binding weakly in healthy tissues.²⁵

Meanwhile, next-generation antibodies like botensilimab are already in clinical trials, aiming to maintain or improve the efficacy of CTLA-4 blockade while reducing the side effect burden.²⁶ If any of these approaches succeed, they could expand ipilimumab-style treatment to patients who currently cannot tolerate it, including older adults and those with pre-existing autoimmune conditions who are typically excluded from checkpoint inhibitor therapy.

How Ipilimumab Changed Oncology

The significance of ipilimumab extends well beyond its direct clinical use. James Allison’s discovery that blocking CTLA-4 could unleash an anti-tumor immune response earned him the 2018 Nobel Prize in Physiology or Medicine (shared with Tasuku Honjo, who worked on the PD-1 pathway). The drug validated a concept that many oncologists had been skeptical of for decades: that the immune system could be therapeutically turned against established cancers in a way that produced lasting benefit. Before ipilimumab, the idea that a metastatic melanoma patient could be alive and disease-free a decade after treatment was virtually unthinkable.

That proof of concept opened the floodgates. There are now multiple approved checkpoint inhibitors across both the CTLA-4 and PD-1/PD-L1 pathways, with indications spanning dozens of cancer types. The field has moved toward combinations, biomarker-guided treatment selection, and earlier use of immunotherapy (before cancer has become metastatic). Ipilimumab’s role has narrowed somewhat as newer agents with better tolerability have emerged, but it remains a cornerstone of combination regimens in melanoma, kidney cancer, and mesothelioma, and continues to serve as the reference point against which every new CTLA-4 drug is measured.